Preclinical Phase

SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases.  What Happened: The study...

Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University of Utah. A poster presentation showed that paxalisib is active in vitro and in vivo against a range of...

Revelation Biosciences Inc (NASDAQ: REVB) announced positive results in a preclinical model of acute kidney injury (AKI), a chronic kidney disease (CKD).  Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose-dependent manner in the medium and high-...

Silo Pharma Inc (NASDAQ: SILO) has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD). The research was conducted as part of a sponsored research agreement with Columbia University in New York.  Silo Pharma's...

Solid Biosciences Inc (NASDAQ: SLDB) presented additional data characterizing AAV-SLB101, a novel adeno-associated virus (AAV) vector designed for improved transduction efficiency and biodistribution to muscle cells.  In studies in wild-type mice, the mdx mouse model of...

Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve.  At 30...

Gain Therapeutics Inc (NASDAQ: GANX) announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson's Disease. The study was conducted using human-induced pluripotent stem cells (...

Beam Therapeutics Inc (NASDAQ: BEAM) announced new preclinical data demonstrating the potential of its multiplex base editing approach to reduce hepatitis B surface antigen (HBsAg) expression and prevent viral rebound of hepatitis B virus (HBV) in vivo models.  Base...

Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting.  The first presentation covered preclinical data from BMF-219 in high-grade B-cell lymphoma and multiple myeloma.  BMF-219 exhibits...

Verve Therapeutics Inc (NASDAQ: VERV) announced new preclinical data supporting the nomination of the company's second product candidate, VERVE-201.  VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and...

Homology Medicines Inc (NASDAQ: FIXX) announced the details of HMI-204, its optimized, in vivo, one-time gene therapy candidate for metachromatic leukodystrophy (MLD).  Following a single I.V. administration in the MLD animal model, the candidate crossed the blood-brain barrier...

Vaxxinity Inc (NASDAQ: VAXX) announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates. The company also selected VXX-401 to pursue as its anti-PCSK9 vaccine candidate to treat hypercholesterolemia.  The company plans to...

Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model. HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer'...

Aditxt Inc's (NASDAQ: ADTX) therapeutic program Adimune has completed a toxicology study indicating a favorable safety profile of ADI-100 for rejection of transplanted organs, skin allografting, autoimmune diseases, and allergies. The company says the completion of preclinical...

Omega Therapeutics Inc (NASDAQ: OMGA) has presented new preclinical data on its lead product candidate, OTX-2002, in multiple models of hepatocellular carcinoma. In non-human primates, treatment with OTX-2002 resulted in a durable reduction of MYC mRNA levels in the liver consistent...